share_log

HC Wainwright & Co. Initiates Coverage On Anebulo Pharmaceuticals With Buy Rating, Announces Price Target of $6

Benzinga ·  Sep 18, 2023 18:33

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy rating and announces Price Target of $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment